<DOC>
	<DOC>NCT01716585</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of ABT-450, ritonavir and ABT-267 (ABT-450/r/ABT-267; ABT-267 also known as ombitasvir) and ABT-333 (also known as dasabuvir) co-administered with ribavirin (RBV) in hepatitis C virus genotype 1 infected treatment-naïve adults.</brief_summary>
	<brief_title>A Study to Evaluate Chronic Hepatitis C Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Females must be postmenopausal for at least 2 years or surgically sterile or practicing specific forms of birth control Chronic hepatitis C, genotype 1infection and HCV RNA level greater than 10,000 IU/mL at screening Subject has never received antiviral treatment for hepatitis C infection No evidence of liver cirrhosis Positive screen for drugs or alcohol Significant sensitivity to any drug Use of contraindicated medications within 2 weeks of dosing Certain predefined abnormal laboratory tests Positive hepatitis B surface antigen or antihuman immunodeficiency virus antibody</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Hepatitis C Virus</keyword>
	<keyword>Hepatitis C Genotype 1</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Treatment-Naïve</keyword>
	<keyword>Interferon-Free</keyword>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>Viekira Pak</keyword>
	<keyword>ombitasvir</keyword>
	<keyword>paritaprevir</keyword>
	<keyword>dasabuvir</keyword>
</DOC>